EUVIMEDEUVIMED entdecken
Open Access

Thiadiazolo‐Triazolo‐Pyrimidine Hybrids as Dual Aurora A/ERK Inhibitors: Design, Synthesis, and Apoptotic Activity

Mai A E Mourad iD, Amal Hofni iD, Ahmed A E Mourad iD

Drug Development Research · 2026

DOI: 10.1002/ddr.70364 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Mai A E Mourad und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Chemistry Department, Faculty of Pharmacy, Port-Said University, Port-Said, Egypt. Hauptthemen laut MEDLINE: Aurora Kinase A, Pyrimidines, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant activation of Aurora A kinase causes mitotic spindle assembly, chromosome segregation, and cell cycle progression, leading to genomic instability as well as disruption of several tumor suppressors. Furthermore, ERK has largely emerged as a survival signaling pathway controlling cell proliferation, differentiation, and metastasis. Unfortunately, this pathway is overexpressed in most of the human malignancies. In efforts to develop innovative inhibitors targeting Aurora A/ERK signaling pathway, a novel series of thiadiazolo‐, triazolo‐pyrimidine hybrids have been designed, synthesized, and assessed for their ability to block Aurora A/ERK and induce apoptosis. Cytotoxicity of the synthesized hybrids was examined against MCF‐7, HCT‐116 and A549 cell lines. Among the synthesized hybrids, 9a , 9c , and 14b demonstrated higher cytotoxic action than alisertib and GDC‐0994 against the MCF‐7 and A549 cancer cell lines. IC 50 values for these hybrids were 2.59 ± 0.13, 4.63 ± 0.25, and 5.77 ± 0.38, respectively, against MCF‐7 cell line and were 3.61 ± 0.19, 3.85 ± 0.21, and 4.23 ± 0.15, respectively, against A549. The selected hybrids significantly suppressed p‐Aurora A kinase level as well as p‐ERK1/2 level and its upstream regulators p‐SRC, p‐c‐RAF, p‐MEK1/2; meanwhile, ERK downstream effectors FOXO3a level was upregulated, and c‐Myc was downregulated, in a dose‐dependent manner. The selected hybrids significantly decreased the expression of Bcl‐2 protein while increasing the levels of p53 , caspase‐7, caspase‐9, and Bax. They effectively induced pre‐G1 phase, G0/G1 phase apoptosis, and G2/M phase arrest. The synthesized hybrids possessed favorable binding interactions in the molecular docking investigations as well as appropriate drug‐like characteristics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aurora Kinase APyrimidinesAntineoplastic AgentsProtein Kinase InhibitorsTriazolesExtracellular Signal-Regulated MAP KinasesHumansApoptosisDrug DesignMCF-7 CellsCell Line, TumorMolecular Docking SimulationA549 CellsHCT116 CellsCell Proliferation

Stichwörter der Autor:innen

ERKaurorapyrimidine

Substanzen

Aurora Kinase APyrimidinesAntineoplastic AgentsProtein Kinase InhibitorsTriazolesExtracellular Signal-Regulated MAP Kinases

Autor:innen und Institutionen

  • Medicinal Chemistry Department, Faculty of Pharmacy, Port-Said University, Port-Said, Egypt.
  • Medicinal Chemistry Department, Faculty of Pharmacy, East Port-Said National University, Port-Said, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Qena University, Qena, Egypt.
  • Pharmacology and Toxicology Department, Faculty of Pharmacy, Port-Said University, Port-Said, Egypt.
  • Pharmacology and Toxicology Department, Faculty of Pharmacy, East Port-Said National University, Port-Said, Egypt.

ORCID-Profile: Mai A E Mourad, Amal Hofni, Ahmed A E Mourad

Zitieren

APA

Mourad, M. A. E., Hofni, A., & Mourad, A. A. E. (2026). Thiadiazolo‐Triazolo‐Pyrimidine Hybrids as Dual Aurora A/ERK Inhibitors: Design, Synthesis, and Apoptotic Activity. Drug Development Research. https://doi.org/10.1002/ddr.70364

Vancouver

Mourad MAE, Hofni A, Mourad AAE. Thiadiazolo‐Triazolo‐Pyrimidine Hybrids as Dual Aurora A/ERK Inhibitors: Design, Synthesis, and Apoptotic Activity. Drug Development Research. 2026. doi:10.1002/ddr.70364

BibTeX
@article{Mourad2026,
  author = {Mourad, Mai A E and Hofni, Amal and Mourad, Ahmed A E},
  title = {Thiadiazolo‐Triazolo‐Pyrimidine Hybrids as Dual Aurora A/ERK Inhibitors: Design, Synthesis, and Apoptotic Activity},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70364}
}
Kostenlos starten →